Skip to main content

Best practices in radiopharmaceutical chemistry

  1. During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due ...

    Authors: Thomas Erik Wuensche, Serge Lyashchenko, Guus A. M. S. van Dongen and Danielle Vugts
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:40
  2. In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology ha...

    Authors: Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen and Erik de Blois
    Citation: EJNMMI Radiopharmacy and Chemistry 2024 9:9
  3. The positron emitting isotope fluorine-18 (18F) possesses almost ideal physicochemical properties for the development of radiotracers for diagnostic molecular imaging employing positron emission tomography (PET)....

    Authors: Simon Blok, Carmen Wängler, Peter Bartenstein, Klaus Jurkschat, Ralf Schirrmacher and Simon Lindner
    Citation: EJNMMI Radiopharmacy and Chemistry 2023 8:25
  4. The radiometal gallium-68 (68Ga) is increasingly used in diagnostic positron emission tomography (PET), with 68Ga-labeled radiopharmaceuticals developed as potential higher-resolution imaging alternatives to trad...

    Authors: Bryce J. B. Nelson, Jan D. Andersson, Frank Wuest and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:27